- Home
- SPRO vs ZNTL Comparison
SPRO vs ZNTL Comparison
Compare SPRO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- ZNTL
- Stock Information
- Founded
- SPRO 2013
- ZNTL 2014
- Country
- SPRO United States
- ZNTL United States
- Employees
- SPRO N/A
- ZNTL N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- ZNTL Health Care
- Exchange
- SPRO Nasdaq
- ZNTL Nasdaq
- Market Cap
- SPRO 107.5M
- ZNTL 105.8M
- IPO Year
- SPRO 2017
- ZNTL 2020
- Fundamental
- Price
- SPRO $1.87
- ZNTL $1.99
- Analyst Decision
- SPRO Buy
- ZNTL Buy
- Analyst Count
- SPRO 4
- ZNTL 7
- Target Price
- SPRO $5.00
- ZNTL $8.46
- AVG Volume (30 Days)
- SPRO 798.2K
- ZNTL 784.9K
- Earning Date
- SPRO 08-12-2025
- ZNTL 08-06-2025
- Dividend Yield
- SPRO N/A
- ZNTL N/A
- EPS Growth
- SPRO N/A
- ZNTL N/A
- EPS
- SPRO N/A
- ZNTL N/A
- Revenue
- SPRO $48,576,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- SPRO N/A
- ZNTL N/A
- Revenue Next Year
- SPRO N/A
- ZNTL N/A
- P/E Ratio
- SPRO N/A
- ZNTL N/A
- Revenue Growth
- SPRO N/A
- ZNTL N/A
- 52 Week Low
- SPRO $0.51
- ZNTL $1.01
- 52 Week High
- SPRO $3.22
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- SPRO 35.23
- ZNTL 78.59
- Support Level
- SPRO $1.80
- ZNTL $1.55
- Resistance Level
- SPRO $2.38
- ZNTL $1.70
- Average True Range (ATR)
- SPRO 0.12
- ZNTL 0.12
- MACD
- SPRO -0.02
- ZNTL 0.05
- Stochastic Oscillator
- SPRO 12.07
- ZNTL 91.43
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.